Astellas ends work on anti-osteopontin antibody for rheumatoid arthritis
This article was originally published in Scrip
Astellas has terminated a development programme for its lead anti-human osteopontin antibody, ASK8007, for rheumatoid arthritis, following disappointing results from a Phase I trial.
You may also be interested in...
While disappointing result will probably put an end to single-drug plans in ovarian cancer, the blockbuster anti-PD-1 immunotherapy remains in combination development for the indication.
Japanese firm in discussions with regulator as high-need novel therapy for spinocerebellar degeneration misses endpoint but shows promise in pooled analysis.